STLN Starling Oncology, Inc. - Common Stock
NASDAQ close Oct 2, 2026STLN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
STLN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.08 | $-0.07 | -22.5% | |
| March 31, 2026 | $-0.02 | $-0.08 | 74.7% | |
| Dec. 31, 2025 | $-0.06 | $-0.09 | 34.6% | |
| Sept. 30, 2025 | $-0.14 | $-0.12 | -21.1% |
Company insiders 18 insiders · 8 officers · 9 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Daniel Virnich | Chief Executive Officer | March 31, 2025 A | 1,807,697 | 0 | 0 | $0 |
| Robert Ross Carter | Chief Financial Officer | March 31, 2025 A | 236,775 | 0 | 0 | $0 |
| Mihir Shah | Chief Financial Officer | May 21, 2024 A | 474,931 | 0 | 0 | $0 |
| Scott Dalgleish | Chief Financial Officer | March 21, 2022 A | 151,008 | 0 | 0 | $0 |
| Jeremy Castle | Chief Operating Officer | March 31, 2025 A | 252,667 | 0 | 0 | $0 |
| Matthew P Miller | Chief Operating Officer | Dec. 16, 2022 P | 175,325 | 0 | 0 | $0 |
| Yale Podnos | Chief Medical Officer | March 31, 2025 A | 236,137 | 0 | 0 | $0 |
| Diona Simoneit | Chief Accounting Officer | Nov. 15, 2022 S | 29,318 | 0 | 0 | $0 |
| Gabriel Ling | Director | Nov. 20, 2025 A | 333,539 | 0 | 0 | $0 |
| Karen Marie Johnson | Director | Nov. 20, 2025 A | 288,286 | 0 | 0 | $0 |
| Brad Hively | Director | Nov. 20, 2025 A | 697,054 | 0 | 0 | $0 |
| Anne Mcgeorge | Director | Nov. 20, 2025 A | 291,370 | 0 | 0 | $0 |
| Mohit Kaushal | Director | Nov. 20, 2025 A | 268,302 | 0 | 0 | $0 |
| Mark L Pacala | Director | Nov. 20, 2025 A | 256,761 | 0 | 0 | $0 |
| Richard A Barasch | Director | Nov. 22, 2024 A | 417,193 | 0 | 0 | $0 |
| Maeve O'Meara | Director | Nov. 17, 2022 A | 42,700 | 0 | 0 | $0 |
| Ravi Sarin | Director | Nov. 17, 2022 A | 45,899 | 0 | 0 | $0 |
| Chernett Jorey | 10% owner | Aug. 13, 2026 S | 10,660,858 | 1 | 1 | $77,856 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 5 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0.35% | 230,802 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.11% | 260,512 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.02% | 550,738 SH | Sept. 11, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 1,964,373 SH | Sept. 11, 2026 | Daily |
| IWN · iShares Trust | · | 149,650 SH | Sept. 11, 2026 | Daily |
STLN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
5 analysts · 2026-09-28Mean target $9.00 +41.7%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| STLN | · | · | · | · | · | · |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | · |
| SGRY | $2.00B | -25.3 | 6.2% | -2.4% | -4.5% | · |
| NUTX | $1.17B | 15.7 | 82.4% | 8.1% | 30.6% | 50.8% |
| ARDT | $1.26B | 9.2 | 6.0% | 2.1% | 11.2% | · |
| USPH | · | 55.0 | 16.3% | 5.1% | 8.2% | 19.2% |
| CYH | $433M | 0.8 | -1.2% | 4.1% | -30.8% | · |
| JYNT | $123M | 45.9 | 5.2% | 5.3% | 16.3% | · |
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.